2. Search Result
Search Result
Results for "

Hyperlipidemic mice

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-173217
    PPARα agonist 5

    		PPAR Phosphatase Cardiovascular Disease Metabolic Disease
    PPARα agonist 5 is an orally available, selective partial agonist of PPARα (EC50: 3 nM). PPARα agonist 5 reduces lipid accumulation and upregulates key PPARα target genes, exerting anti-fatty liver effects. PPARα agonist 5 also exhibits significant hypolipidemic and hypoglycemic effects through partial PPARγ agonist activity and mild inhibition of protein tyrosine phosphatase 1B (PTP1B) (IC50: 79.1 μM). PPARα agonist 5 has a good safety profile and can be used in the study of type 2 diabetes with dyslipidemia .
    PPARα agonist 5
  • HY-181876
    F44-S101

    		FXR Metabolic Disease
    F44-S101 is an orally active, potent, and selective gut-restricted FXR antagonist with an IC50 of 0.48 μM and lipid-lowering activity. F44-S101 selectively antagonizes intestinal FXR, feedback-activates hepatic FXR, promotes cholesterol metabolism and reduces lipid accumulation. F44-S101 decreases total cholesterol, triglyceride and low-density lipoprotein cholesterol levels. F44-S101 can be used in studies related to hyperlipidemia .
    F44-S101
  • HY-181474
    CF-Vanillin

    		Keap1-Nrf2 Heme Oxygenase (HO) PPAR Interleukin Related SOD Metabolic Disease Inflammation/Immunology
    CF-Vanillin is an orally active hypolipidemic/hepatic protector with strong binding affinity for PPAR-α. CF-Vanillin exerts antioxidant and anti-inflammatory effects by activating the Nrf2/HO-1 signaling pathway. CF-Vanillin reduces triglyceride and total cholesterol levels and alleviates liver injury. CF-Vanillin can be used in the research of diseases such as hyperlipidemia and liver injury .
    CF-Vanillin
  • HY-181520
    ABCA1 inducer 3

    		ATP-binding cassette (ABC) transporters Metabolic Disease
    ABCA1 inducer 3 (Compound 85) is an orally active ABCA1 inducer and lipid-modulating agent. ABCA1 inducer 3 increases ABCA1 expression. ABCA1 inducer 3 upregulates hepatic Abcg5 and Abcg8 mRNA expression. ABCA1 inducer 3 promotes cholesterol efflux. ABCA1 inducer 3 improves hyperlipidemia .
    ABCA1 inducer 3
  • HY-179591
    BGT-002

    326E

    		 ATP Citrate Lyase PPAR Metabolic Disease
    BGT-002 (326E) is an orally active dual ACLY inhibitor and PPARα agonist. BGT-002 reduces lipogenesis by inhibiting synthesis and promoting efflux. BGT-002 demonstrates efficacy in ameliorating metabolic dysfunction-associated steatohepatitis (MASH) and improving hyperlipidemia in vivo. BGT-002 can be used for hypercholesterolemia and MASH research .
    BGT-002

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: